Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health Services | 1 | 2015 | 39 | 0.470 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 147 | 0.420 |
Why?
|
| Occupational Health | 1 | 2015 | 197 | 0.410 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2024 | 86 | 0.370 |
Why?
|
| Health Promotion | 1 | 2015 | 518 | 0.340 |
Why?
|
| Calorimetry, Indirect | 1 | 2025 | 33 | 0.230 |
Why?
|
| Autism Spectrum Disorder | 2 | 2017 | 183 | 0.200 |
Why?
|
| Neuronal Plasticity | 1 | 2024 | 153 | 0.190 |
Why?
|
| Hippocampus | 1 | 2024 | 280 | 0.190 |
Why?
|
| Salicylates | 1 | 2021 | 9 | 0.170 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 1308 | 0.170 |
Why?
|
| Colitis | 1 | 2021 | 78 | 0.160 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2018 | 17 | 0.140 |
Why?
|
| Neurons | 1 | 2024 | 949 | 0.140 |
Why?
|
| Lipogenesis | 1 | 2018 | 68 | 0.140 |
Why?
|
| Siblings | 1 | 2017 | 43 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 184 | 0.120 |
Why?
|
| Dermatology | 1 | 2017 | 72 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 143 | 0.120 |
Why?
|
| Connecticut | 1 | 2015 | 90 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2016 | 164 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 311 | 0.120 |
Why?
|
| Macrophages | 1 | 2021 | 1060 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 224 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 123 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2016 | 205 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 320 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 438 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 112 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2015 | 228 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2015 | 497 | 0.100 |
Why?
|
| Adolescent | 4 | 2017 | 6377 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2015 | 1018 | 0.090 |
Why?
|
| Telemedicine | 1 | 2017 | 361 | 0.090 |
Why?
|
| Male | 9 | 2024 | 31065 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 726 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 924 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 4831 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2015 | 2101 | 0.070 |
Why?
|
| Stroke | 1 | 2016 | 1215 | 0.060 |
Why?
|
| Female | 7 | 2017 | 34113 | 0.060 |
Why?
|
| Adult | 4 | 2017 | 17409 | 0.060 |
Why?
|
| Humans | 9 | 2025 | 65534 | 0.060 |
Why?
|
| Middle Aged | 4 | 2017 | 18261 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 3468 | 0.060 |
Why?
|
| Sentinel Surveillance | 1 | 2005 | 20 | 0.060 |
Why?
|
| Dendritic Spines | 1 | 2024 | 13 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2005 | 89 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2024 | 142 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2005 | 74 | 0.050 |
Why?
|
| Animals | 4 | 2025 | 21533 | 0.050 |
Why?
|
| Mice | 3 | 2024 | 11209 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2017 | 877 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2025 | 395 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2005 | 314 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2510 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 56 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2021 | 40 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2017 | 6880 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 738 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 3788 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 30 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2018 | 187 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 5441 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 57 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 956 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2017 | 51 | 0.030 |
Why?
|
| Child | 2 | 2017 | 4681 | 0.030 |
Why?
|
| Spain | 1 | 2016 | 33 | 0.030 |
Why?
|
| Metformin | 1 | 2017 | 76 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2017 | 83 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 977 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2016 | 99 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 113 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 3355 | 0.030 |
Why?
|
| Rats | 1 | 2018 | 2018 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 800 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 997 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1172 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1186 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2015 | 152 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 861 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 694 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1410 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1156 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1123 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 2077 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 595 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 1441 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2699 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1393 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2005 | 25 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2005 | 76 | 0.010 |
Why?
|
| United States | 1 | 2017 | 8130 | 0.010 |
Why?
|
| Health Services Research | 1 | 2005 | 271 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 210 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 14941 | 0.010 |
Why?
|